

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**Pembrolizumab with carboplatin and paclitaxel for  
untreated metastatic squamous non-small-cell lung cancer  
[ID1683]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- |   |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

No potential equality issues have been identified during the scoping process.
---

- |   |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

Not applicable.
-----------------

- |  |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

Not applicable.
-----------------

- |  |
|--|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? |
|--|

Not applicable.

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 30/01/2020